Evotec stock reports weaker 2026 guidance ahead of results

Published on 10/05/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock traded at EUR 2.92 on October 5, 2026, while first-half revenue fell 19.2 percent to EUR 300.1 million. The 2026 EBITDA outlook remains negative.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) traded at EUR 2.92 on Xetra at 12:28 p.m. CEST on October 5, 2026, with the biotechnology group facing a sharply weaker 2026 outlook and a key quarterly report scheduled for November 5. The central question is whether the Horizon savings program can offset delayed milestones and weaker revenue conversion.

Guidance points to another loss

According to Borse Express on September 15, 2026, Evotec cut its 2026 revenue guidance to EUR 570 million to EUR 610 million from EUR 700 million to EUR 780 million. Adjusted EBITDA is now expected at minus EUR 70 million to minus EUR 105 million, compared with the previous range of zero to EUR 40 million.

The latest operating figures explain the reset. Evotec generated EUR 143.5 million of revenue in the second quarter of 2026, down 16 percent from EUR 171.2 million in the prior-year quarter, while first-half revenue reached EUR 300.1 million and adjusted EBITDA was minus EUR 42.7 million, according to Borse Express.

Analyst target stays above price

According to Finanzen on September 25, 2026, Berenberg kept Evotec at Hold with a EUR 3.60 price target. The target lies 23.3 percent above the EUR 2.92 Xetra price.

The published analyst summary lists one Buy, four Holds and zero Sells across five houses, with a 12-month consensus target of EUR 3.60, according to Borse Express. That spread leaves execution, rather than valuation alone, as the immediate test for the stock.

November report sets next checkpoint

Borse Express reported on September 29, 2026, that Evotec plans to publish its third-quarter report on November 5, 2026. The date gives investors a defined checkpoint for savings, partnerships and milestone timing.

Evotec stock stays near yearly low

Evotec stock traded at EUR 2.92 on Xetra on October 5, 2026, with an intraday range of EUR 2.90 to EUR 2.97 and volume of 140,858 shares. The 52-week range was EUR 2.71 to EUR 7.30, placing the stock 59.9 percent below its yearly high.